TP53 and B-cell chronic lymphocytic leukemia: As monotherapy and in combination with anti-CD20 monoclonal antibodies, it is effective for treating CLL patients including those with high-risk 17p deletion and/or TP53-deficient disease, with high rates of durable complete responses7–9.